Eli Lilly CEO: $25B deal spree targets post-obesity growth into 2030s
Eli Lilly CEO says the company’s $25B deal spree is about building growth beyond obesity into the 2030s.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.